Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Penumbra (PEN)
NYSE:PEN
Holding PEN?
Track your performance easily
PEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$148.00 - $277.34
Previous Close$237.11
Volume248.90K
Average Volume (3M)385.42K
Market Cap
$9.10B
Enterprise Value$9.04B
Total Cash (Recent Filing)$291.02M
Total Debt (Recent Filing)$226.69M
Price to Earnings (P/E)275.4
Beta0.85
Next Earnings
Feb 25, 2025EPS Estimate
$0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.86
Shares Outstanding38,379,199
10 Day Avg. Volume349,072
30 Day Avg. Volume385,422
Standard Deviation0.14
R-Squared0.04
Alpha0.00972
Financial Highlights & Ratios
Price to Book (P/B)8.24
Price to Sales (P/S)7.84
Price to Cash Flow (P/CF)40.90
P/FCF Ratio45.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.76
Enterprise Value/Gross Profit13.24
Enterprise Value/Ebitda-2.67K
Forecast
1Y Price Target
$230.43Price Target Upside-3.67% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Penumbra News
PremiumCompany Announcements
Penumbra, Inc. Sees Strong Q3 Revenue GrowthBulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe announced enrollment completion is viewed as an incremental positive for one of PEN's largest segments, which could support potential FDA approval and initial revenue contribution for PEN's Thunderbolt in Stroke.
Market Share And GrowthPEN's recent CAVT launches in both Arterial and VTE have helped drive meaningful market share gains for PEN in these segments.
Regulatory ApprovalsThere were significant regulatory approvals, including US FDA clearance and CE marks for key products, which are expected to contribute to future growth.
Bears Say
Market PerformancePEN has been a notable underperformer YTD, with several factors weighing on the stock including a lack of clear visibility on the current composition of revenue between the different commercial markets.
Product GrowthThrombectomy growth slowed to 14% in 3Q24 from 25% in 2Q24.
Revenue GuidanceCaution is advised regarding 2025 revenue guidance as there is a belief that current expectations might be too optimistic.
---
Ownership Overview
3.52% Insiders
43.34% Mutual Funds
― Other Institutional Investors
31.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PEN FAQ
What was Penumbra’s price range in the past 12 months?
Penumbra lowest stock price was $148.00 and its highest was $277.34 in the past 12 months.
What is Penumbra’s market cap?
Currently, no data Available
When is Penumbra’s upcoming earnings report date?
Penumbra’s upcoming earnings report date is Feb 25, 2025 which is in 94 days.
How were Penumbra’s earnings last quarter?
Penumbra released its earnings results on Oct 30, 2024. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.687 by $0.163.
Is Penumbra overvalued?
According to Wall Street analysts Penumbra’s price is currently Overvalued.
Does Penumbra pay dividends?
Penumbra does not currently pay dividends.
What is Penumbra’s EPS estimate?
Penumbra’s EPS estimate is $0.88.
How many shares outstanding does Penumbra have?
Penumbra has 38,379,200 shares outstanding.
What happened to Penumbra’s price movement after its last earnings report?
Penumbra reported an EPS of $0.85 in its last earnings report, beating expectations of $0.687. Following the earnings report the stock price went up 8.32%.
Which hedge fund is a major shareholder of Penumbra?
Among the largest hedge funds holding Penumbra’s share is PRIMECAP Management Co. It holds Penumbra’s shares valued at 8M.
---
Penumbra Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$230.43 (-3.67% Downside)
$230.43 (-3.67% Downside)
Blogger Sentiment
Bullish
PEN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 650.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.77%
12-Months-Change
Fundamentals
Return on Equity
3.13%
Trailing 12-Months
Asset Growth
0.73%
Trailing 12-Months
Company Description
Penumbra
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
---
PEN Earnings Call
Q3 2024
0:00 / 0:00
---
PEN Stock 12 Month Forecast
Average Price Target
$230.43
▼(-3.67% Downside)
Technical Analysis
Best Analysts Covering PEN
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+14.27%
reiterated a buy rating 23 days ago
Copying David Rescott's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +14.27% per trade.
---